Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD)

Core Insights - Kezar Life Sciences, Inc. is a clinical-stage biotechnology company focused on developing small molecule therapeutics for immune-mediated diseases [1] - The company announced two presentations from the completed Phase 2a PORTOLA clinical trial for autoimmune hepatitis at The Liver Meeting 2025 [1] - The event is organized by the American Association for the Study of Liver Disease and will take place from November 7-11 in Washington, DC [1]